REDUCING PACLITAXEL-INDUCED PERIPHERAL NEUROTOXICITY VIA LIPOSOMAL DRUG TARGETING

Paclitaxel (PTX) is a highly effective chemotherapeutic agent widely used in breast cancer treatment, but its clinical application is significantly limited by peripheral neurotoxicity. Innovative drug delivery systems are needed to selectively release PTX at the tumor site while minimizing neuronal damage. In this proof-ofconcept study, we developed and characterized PTX-loaded liposomes functionalized with a metalloproteinase-sensitive lipopeptide (MSLP), exploiting the overexpression of metalloproteinases in the tumor microenvironment to achieve site-specific drug release. Liposomes were prepared via thin-film hydration followed by extrusion, resulting in four formulations: PTX-loaded liposomes (LipoPTX), metalloproteinase-sensitive functionalized PTX liposomes (MSLP-LipoPTX), and unloaded liposomes (functionalized or not). Antitumor activity was evaluated in MCF-7 breast cancer cells using the MTT assay. Neurotoxicity was assessed both in vitro, using primary cultures of adult mouse sensory neurons, and in vivo, in transgenic zebrafish embryos (Tg(isl2b:GFP)zb7), analyzing morphological, behavioral, and molecular endpoints. Our results demonstrated that both LipoPTX and MSLP-LipoPTX preserved the anticancer activity of free PTX while significantly reducing its neurotoxic effects. In sensory neuron cultures, liposomal formulations induced only mild neurite shortening compared with free PTX. In zebrafish embryos, treatment with LipoPTX and MSLP-LipoPTX was associated with lower mortality, fewer caudal fin abnormalities, and improved responsiveness to mechanical stimuli. Overall, these findings suggest that functionalized liposomes can effectively deliver PTX while mitigating peripheral neurotoxicity in both in vitro and in vivo models. This strategy offers a promising approach to enhance the therapeutic index of PTX and supports further investigations in zebrafish xenograft models of human breast cancer to validate its translational potential.

Institutions

Publication Details

Journal
European Journal of Histochemistry
Published
2025-12-12
DOI
https://doi.org/10.4081/ejh.2025.4503
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

REDUCING PACLITAXEL-INDUCED PERIPHERAL NEUROTOXICITY VIA LIPOSOMAL DRUG TARGETING

European Journal of Histochemistry
Nanoparticle-Based Drug Delivery
article

REDUCING PACLITAXEL-INDUCED PERIPHERAL NEUROTOXICITY VIA LIPOSOMAL DRUG TARGETING

article en

Abstract

Paclitaxel (PTX) is a highly effective chemotherapeutic agent widely used in breast cancer treatment, but its clinical application is significantly limited by peripheral neurotoxicity. Innovative drug delivery systems are needed to selectively release PTX at the tumor site while minimizing neuronal damage. In this proof-ofconcept study, we developed and characterized PTX-loaded liposomes functionalized with a metalloproteinase-sensitive lipopeptide (MSLP), exploiting the overexpression of metalloproteinases in the tumor microenvironment to achieve site-specific drug release. Liposomes were prepared via thin-film hydration followed by extrusion, resulting in four formulations: PTX-loaded liposomes (LipoPTX), metalloproteinase-sensitive functionalized PTX liposomes (MSLP-LipoPTX), and unloaded liposomes (functionalized or not). Antitumor activity was evaluated in MCF-7 breast cancer cells using the MTT assay. Neurotoxicity was assessed both in vitro, using primary cultures of adult mouse sensory neurons, and in vivo, in transgenic zebrafish embryos (Tg(isl2b:GFP)zb7), analyzing morphological, behavioral, and molecular endpoints. Our results demonstrated that both LipoPTX and MSLP-LipoPTX preserved the anticancer activity of free PTX while significantly reducing its neurotoxic effects. In sensory neuron cultures, liposomal formulations induced only mild neurite shortening compared with free PTX. In zebrafish embryos, treatment with LipoPTX and MSLP-LipoPTX was associated with lower mortality, fewer caudal fin abnormalities, and improved responsiveness to mechanical stimuli. Overall, these findings suggest that functionalized liposomes can effectively deliver PTX while mitigating peripheral neurotoxicity in both in vitro and in vivo models. This strategy offers a promising approach to enhance the therapeutic index of PTX and supports further investigations in zebrafish xenograft models of human breast cancer to validate its translational potential.

European Journal of HistochemistryVol. 69(S3)
GTx (United States) (US)
Good health and well-being
Openalex Percentile: Top 46%
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

REDUCING PACLITAXEL-INDUCED PERIPHERAL NEUROTOXICITY VIA LIPOSOMAL DRUG TARGETING · European Journal of Histochemistry (2025) | TGRS Research Map | TGRS